Navigation Links
Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL

NEW YORK, September 12, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Oncolytics Biotech, Inc. (NASDAQ: ONCY), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Sangamo BioSciences, Inc. (NASDAQ: SGMO), and PDL BioPharma, Inc. (NASDAQ: PDLI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Aegerion Pharmaceuticals, Inc. Research Report

On September 8, 2013, Aegerion Pharmaceuticals, Inc. (Aegerion) announced that it has received orphan drug designation from Japan's Ministry of Labour, Health and Welfare for lomitapide which is used in the treatment of homozygous familial hypercholesterolemia (HoFH). The Company informed that it is currently conducting a pharmacokinetic/pharmacodynamics (PK/PD) study of lomitapide required by the Japanese regulatory authorities and expects the study to be completed in Q4 2013. Post the completion of the study, the Company also plans to conduct a small therapeutic study of lomitapide in Japanese adult HoFH patients. The Full Research Report on Aegerion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


Oncolytics Biotech, Inc. Research Report

On September 9, 2013, Oncolytics Biotech, Inc. (Oncolytics) announced final tumour response data from its US Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021). Oncolytics stated that the study enrolled patients with metastatic stage IIIB or stage IV, or recurrent, squamous cell carcinoma of the lung, who were chemotherapy-naïve for their metastatic or recurrent cancer. According to Oncolytics, the analysis examined percent best overall tumour responses between pre-treatment and up to six treatment cycles and revealed that out of 25 evaluable patients who had more than one cycle of therapy, 92% exhibited overall tumour shrinkage. Oncolytics also informed that final progression-free survival and safety data for the study will be reported in late 2013. The Full Research Report on Oncolytics Biotech, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


Merrimack Pharmaceuticals, Inc. Research Report

On August 28, 2013, Merrimack Pharmaceuticals, Inc. (Merrimack) announced that it has reached its enrollment goal in the NAPOLI-1 trial, a randomized Phase 3 study of MM-398, with or without 5-fluorouracil (5-FU) and leucovorin (LV), versus 5-FU and LV, in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy. Eliel Bayever, M.D., Vice President of Merrimack and Medical Director of MM-398 said, "To our knowledge this is one of the largest controlled studies ever conducted in this patient population, which has very few treatment options." The Full Research Report on Merrimack Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


Sangamo BioSciences, Inc. Research Report

On August 26, 2013, Sangamo BioSciences, Inc. (Sangamo) announced that it has signed a definitive agreement to acquire Ceregene, Inc. (Ceregene), a privately held biotechnology company focused on developing adeno-associated virus (AAV) gene therapies.The Company informed that in accordance with the terms of the agreement, Sangamo will issue to the stockholders of Ceregene 100,000 shares of Sangamo's common stock, representing less than 0.2% of Sangamo's total shares outstanding. Further, the Company has agreed to make contingent earn-out payments to the stockholders of Ceregene based upon revenues generated from license or sales transaction of certain existing products of Ceregene. Sangamo expects the acquisition to close in September 2013, and does not expect it to have any impact on the Company's financial guidance for full-year 2013 operating expenses or year-end cash balance. The Full Research Report on Sangamo BioSciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


PDL BioPharma, Inc. Research Report

On September 9, 2013, PDL BioPharma, Inc. (PDL) announced revenue guidance for Q3 2013. The Company expects revenues of approximately $97 million, as compared with revenues of $85 million reported in Q3 2012, representing an increase of 14.1% YoY. The Company informed that its revenue guidance is driven by increased Q2 2013 sales for Avastin, Herceptin, Lucentis, Xolair, Kadcyla, Perjeta, and Actemra, for which PDL receives royalties in Q3 2013. The Full Research Report on PDL BioPharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []



  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by an analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at
  5. For any urgent concerns or inquiries, please contact us at
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Investors' Reports
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
2. Puma Biotechnology Announces Completion of Private Placement
3. Animal Biotechnology - Technologies, Markets and Companies
4. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
5. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
6. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
7. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
8. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
9. SuperNova Diagnostics® to Present at Biotech Showcase™ 2012 During JP Morgan Healthcare Conference January 9 - 12
10. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
11. Selexis SA to Present at Biotech Showcase 2012
Post Your Comments:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Global Stem Cells Group announced ... clinics in the cities of Arica and Iquique in northern Chile. The facilities are part ... offer the most advanced protocols and techniques in stem cell medicine to patients from around ...
(Date:11/30/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a leader in ... Business Act on Climate Pledge, alongside more than 140 companies ... Obama Administration to demonstrate an ongoing commitment to climate action ... COP21 Paris climate negotiations. ... Canada . --> BioAmber uses biotechnology to ...
(Date:11/30/2015)...  Culprits beware, a University at Albany research ... is taking crime scene fingerprint identification to a ... -->   --> Photo ... --> Halámek and his team ... concept for identifying whether a culprit is male ...
(Date:11/30/2015)... Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or ... Norman C.W. Wong to its Board of Directors to ... Zenith with a wealth of experience as co-founder of Resverlogix, ... --> --> Dr. Wong ... board of directors. Zenith,s long standing expertise in epigenetics and ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig ... report titled, "DNA Synthesis and Biosecurity: Lessons Learned and ... Department of Health and Human Services guidance for synthetic ... 2010. --> --> ... also has the potential to pose unique biosecurity threats. ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, Inc., ... U.S. distribution of its DNA library preparation products, ... Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has ... preparation of NGS libraries for liquid biopsies--the analysis ... and prognostic applications in cancer and other conditions. ...
(Date:10/29/2015)... October 29, 2015 NXTD ... company focused on the growing mobile commerce market ... that StackCommerce, a leading marketplace to discover and ... Wocket® smart wallet on StackSocial for this holiday ... or the "Company"), a biometric authentication company focused ...
Breaking Biology News(10 mins):